Evaluation of Frailty in Patients With Fibrosing Interstitial Lung Diseases: Prognostic and Therapeutic Impact

Launched by NANTES UNIVERSITY HOSPITAL · May 26, 2025

Keywords

ClinConnect Summary

This clinical trial is looking at how frailty and muscle loss (called sarcopenia) affect patients with fibrosing interstitial lung diseases (ILDs), like idiopathic pulmonary fibrosis, which mainly impacts older adults and can lead to serious health complications. The researchers want to find out if assessing a patient's frailty and muscle strength can help doctors better understand the patient’s health and improve treatment options. Currently, some medications can slow down the progression of these diseases, but they may not work as well for older patients who have other health issues.

To participate in this study, patients must be at least 65 years old, speak French, and have a diagnosis of fibrosing ILD based on specific medical guidelines. They should also be able to attend outpatient appointments. Unfortunately, individuals with certain cognitive difficulties or specific early-stage lung patterns on their CT scans will not be eligible. While the trial is not yet recruiting participants, it aims to gather important insights that could lead to better care and treatment decisions for older patients facing these challenging lung diseases.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Patient with fibrosing ILD according to the ATS/ERS/JRS/ALAT 2022 criteria.
• • Patient aged ≥ 65 years.
• • Outpatient consultation (scheduled appointment in an outpatient clinic, day hospital, or weekly hospital stay).
• • French-speaking patient.
• • Patient who has received an information sheet explaining the study and has not expressed opposition to participating in this research.
• Exclusion Criteria:
• • Patient under legal guardianship, curatorship, or judicial protection.
• • Cognitive disorders limiting the use of questionnaires.
• • Patient with a CT scan showing an early usual interstitial pneumonia (UIP) pattern according to the ATS/ERS/JRS/ALAT 2022 classification.